Mixing antioxidants and sun exposure can be dangerous to your health. A new study, published in the September issue of The Journal of Nutrition, details a French study revealing that antioxidant supplements won't protect women against skin cancer -- and they may actually increase the risk of developing the disease.

A team of French researchers assigned almost 7,900 women and more than 5,100 men to take either an oral daily capsule of antioxidant or a placebo that looked the same. The antioxidants included low levels of vitamins C and E, beta-carotene, selenium, and zinc. What they found: the incidence of all skin cancers was higher in the group of women who took the antioxidant.

While there is one limitation to this study -- it did not take into account sunscreen use and its effect on the use of both antioxidants and the sun -- it does serve as another reason to stay out of the sun.

Liver cancer experts attribute the rise in HCC, a highly aggressive cancer sometimes called hepatoma, to an increase decades ago in chronic infection with hepititis C & B and also chronic alcohol consumption. Worldwide liver cancer affects 700,000 people with 18,000 Americans diagnosed in 2006 and over 19,000 estimated to be diagnosed in 2007. The increase of this disease in the United States has doubled in one decade and over 16,000 people are estimated to die from the disease this year.

The rise in the United States is expected to increase. There are now 1.4 million people in the United States infected with HBV and 4 million are infected with HCV. Growing evidence suggests two other diseases now increasingly common in the United States to have significant risk factors for primary liver cancer. Diabetes and obesity.

HCC typically does not have any symptoms until its later stages which makes it difficult to diagnose. Traditional chemo does not treat the disease with much success and liver transplants or resection surgeries are needed. One reason why donors are very important in fighting this disease. When signs and symptoms do arise they might include weight loss, fatigue, pain in the upper right abdomen that may extend to the back and shoulder, feeling full after small meals, accumulation of fluid in the abdomen, nausea, loss of appetite, and jaundice.

Many Americans have begun taking folic acid supplements thinking that it can protect against colon cancer and also cut a person's risk of stroke and heart disease.

In the past, animal studies led researchers to believe that folic acid had these beneficial effects. The National Institutes of Heath funded a clinical trial that enrolled more than 1,000 men and women who previously had polyps removed from their colons.

Those in the study were randomly assigned to take daily pills containing either 1 milligram of folic acid or a placebo. The study showed that those who took the folic acid got just as many new colon polyps as those who took the placebo pills.

Robert Sandler, M.D., chief of the division of gastroenterology and hematology, told WebMD, "We are disappointed and surprised that it didn't work. In fact, there was some evidence that folic acid increased cancer risk."

Males born with undescended testis have and increased risk of developing testicular cancer later in life. The surgical procedure called orchiopexy, can be performed on a child as early as six months of age.

In the New England Journal of Medicine they state that surgery before the age of thirteen for the treatment of undesended testis reduces the risk of testicular cancer compared with having surgery later in life.

The results of a study done by researchers in Sweden concluded that among those who underwent orchiopexy before the age of thirteen had an increased risk of testicular cancer that was slightly more than twofold of the general male population. Those who waited to get the surgery after thirteen years of age had a fivefold risk of developing the disease.

Visit Our Heroes website to contribute to the fight against breast cancer and domestic violence.

On the website you can create your own Avon Breast Cancer Crusade Tribute Fund or a Speak Against Domestic Violence Tribute Fund.

The Our Heroes website explains why a Tribute Fund is a great idea:

• It is an easy way to honor someone dear to you and at the same time contributes to a great cause.
• It allows you to tell your story about the Honoree and why you are supporting this cause.
• It allows you to raise awareness of the importance of fighting against breast cancer or domestic violence.

Go to the Our Heroes website to learn how you can get your own Tribute Fund started!

Time to test your smarts -- about sleep, sun, food, and alcohol.

Just read the following questions, pick an option and then scroll down to determine if you really know what's best for your health.

• Is it healthier to sleep an extra hour or force yourself out of bed in the morning to exercise?

• Is it healthier to spend 15 minutes in the sun without sunscreen or two hours in the sun wearing SPF 30?

• Is it better to have a second glass of wine at dinner or a sinful dessert?

Oh no. I think I 'm headed for melanoma. At the very least, I seem to have a very high risk for developing the disease, thanks to my once-stubborn pursuit of a silly tan.

Think about this:

A review of seven different studies concludes that using a tanning bed under the age of 35 -- I'm so guilty -- can increase the risk of melanoma by 75 percent. Even those who have ever used indoor tanning were 15 percent more likely to develop the disease.

We're talking the deadliest form of skin cancer here. So deadly some experts are recommending strong measures to restrict the use of tanning beds by young people. Adults should be discouraged from tanning, some say, but access should be limited for those under the age of 18.

New Jersey already has regulations in place -- those under 14 are banned from tanning salons and anyone between 14 and 18 must have parental consent.

If I could turn back time, I would listen to my grandma. She told me the sun -- and tanning beds too -- were no good. But I was young. And I didn't care.

Now I'm older. And I care. But it may be too late. It seems this could be one lesson I learn the hard way.

British researchers have found a connection between inflammatory polyarthritis, rheumatoid arthritis, and cancer. The connection -- a 40 percent increase in cancer mortality in patients with both arthritis conditions.

This is a striking finding, say researchers, whose study is published in the March issue of Arthritis & Rheumatism.

"The results of this study demonstrated that five-year cancer survival in patients with IP is substantially reduced in comparison with that in the general population, even after adjusting for differences in age, sex, and cancer site, whereas the overall cancer incidence does not seem to be increased," says study leader Dr. Alan Silman, an epidemiologist with the University of Manchester.

Wyeth officials say their hormone replacement therapy Prempro is not the cause of one Ohio woman's breast cancer. But two jury decisions prove otherwise.

The first jury, in October, awarded Jennie Nelson and her husband $1.5 million in compensatory damages, validating Nelson's claim that her breast cancer -- resulting in a double mastectomy, chemotherapy, and radiation -- was caused by the Prempro she took for six years. When this verdict was thrown out due to a mistrial, a retrial began.

The retrial concluded yesterday -- with a Philadelphia jury awarding the Nelsons this time with $3 million.

"Both times this case has been heard on terms established by Wyeth and still the juries have clearly found that Prempro causes breast cancer," says Nelson's attorney Tobias Millrood, adding that Wyeth puts sales ahead of patient safety.

Wyeth respectfully disagrees and argues that it acted responsibly in the promotion of its hormone replacement products and in disclosing with doctors and patients all therapy-associated health risks.

Millions of women have used Wyeth's hormone replacement therapies to control the effects of menopause, and the company, sanctioned in January to pay $1 million to an Arkansas breast cancer survivor, now faces more than 5,000 lawsuits of this same nature.

Despite a large-scale study revealing drugs like Prempro increase the risk of breast cancer if used for five years or more, the drug still remains on the market. And Wyeth is so sure their drug is not at fault for causing Nelson's breast cancer that they plan to appeal yesterday's verdict.

According to the results of an international study, postmenopausal women who have taken tamoxifen for early stage estrogen-receptor positive breast cancer for two to three years might increase their chances of survival by switching to newer breast cancer drugs called aromatase inhibitors.

Study researchers found this drug switch-up reduced the number of events linked to poor survival by 32 percent -- although no difference has been found in overall survival at this early point in the trial.

"These findings provide some limited evidence to advise all women being administered tamoxifen to switch, even though this approach is not devoid of potentially serious side effects," say experts at the National Cancer Institute.

Side effects appear to be minimal, however, and the up side of treatment with aromatase inhibitors is the fact that they don't seem to carry the risk of death from other causes like with tamoxifen, which can cause stroke or endometrial cancer.

This study is expected to be published in the March 15 issue of the journal Cancer.

As if gum disease is not a painful enough experience, a Harvard study shows the disease can more than double the risk of pancreatic cancer. Additionally, those with a history of gum disease and recent tooth loss have a 2.7-fold increase in risk.

Previous studies have linked gum disease and pancreatic cancer, but smoking -- which contributes to both diseases -- has never been taken into consideration.

Researchers in this study, who controlled for smoking, followed 51,529 men for 16 years and found those who reported gum disease were 64 percent more likely to have pancreatic cancer. Nonsmokers with gum disease were twice as likely to develop the disease.

It was also determined in the study, published in the January 17 issue of the Journal of the National Cancer Institute, that the more severe the gum disease, the higher the cancer risk.

While it is not clear why gum disease is linked to cancer risk, researchers believe perhaps long-term gum infections trigger body-wide inflammation -- and inflamed tissues send chemical signals that promote tumor growth.

The standard dose of some medications are too high and dangerous for the patients, where some patients respond the exact opposite and show that the standard dose is too low to produce beneficial effects. It would seem to be a simple case of age, gender, or genetic differences to explain the individual variability in response to the drugs.

A study at the University of Kansas is reporting that variations in the body's production of hydrogen peroxide, which is believed to serve as a signaling molecule at low levels, can affect the accumulation of drugs inside our cells.

Oxidative stress, an increase in hydrogen peroxide levels, may have an increased response to a given dosage of a drug. This seems to show that it is in our best interest for physicians to provide more individualized dosing of drugs.

Hydrogen peroxide effects could be especially important in therapeutic drugs such as aminophylline, carbamazepine, lithium, carbonate, phenytoin, theophylline and warfarin. The researchers think that small changes in the doses of these drugs could cause either subtherapeutic or toxic results.

In a Phase III trial involving 878 lung cancer patients, the drug bevacizumab, known as Avastin, increased the overall survival rate to 35 percent when combined with the chemotherapy drugs paclitaxel and carboplatin. Patients who were given paclitaxel and carboplatin without Avastin had a 15 percent chance of responding to treatment.

Two months ago, the Food and Drug Administration approved Avastin as a first-line treatment for patients with inoperable, locally advanced, recurrent or metastatic non-squamous, non-small cell lung cancer. Avastin works by stopping the formation of blood vessels that feed oxygen and nutrients needed for tumor growth. Because the drug is a targeted therapy, in that it leaves healthy tissue alone while going after cancer cells, some of the traditional side-effects from conventional chemotherapy, such as hair loss, nausea, or vomiting, are avoided.

According to Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Chief of Hematology/Oncology's Dr. Joan Schiller, "Twenty years ago, we thought no treatment could help patients with advanced lung cancer. Ten years ago, we found that chemotherapy could improve survival of these patients. Now, we are finding out that this very unique drug called Avastin can also help improve survival even more. Avastin is the first of this very exciting family of drugs to be approved for lung cancer, and there are several other drugs of this type under development which may prove to work even better."

The treatment combination of Revlimid (lenalidomide), Oncovin (vincristine), Doxil (pegylated doxorubicin) and dexamethasone appears to be highly effective in multiple myeloma that has recurred or progressed following prior therapies.

According to an article published in the Annals of Oncology, researchers from the Cleveland Clinic conducted a clinical trial to evaluate this combination of drugs. The trial included 62 patients, 75 percent of the patients achieved an anticancer response and 29 percent of patients achieved a complete or near complete disappearance of detectable cancer.

The researchers note that determining treatment choices for those patients who recur after initial therapy is more challenging than treating patients that have not received prior therapy. Multiple myeloma is usually treated with chemotherapy -- however -- new treatments are evolving that are better tolerated, especially in older patients who cannot handle aggressive chemotherapy. The researchers continue to evaluate strategies in order to offer patients individualized treatment options.

Last week The Food and Drug Administration (FDA) approved Taxotere (docetaxel) for the use in combination with cisplatin and fluorouracil prior to radiation therapy for the treatment of patients with inoperable, locally advanced squamous cell carcinoma of the head and neck.

A trial was conducted that included 358 patients with previously untreated, inoperable, locally advanced head and neck cancer. The patients were divided into two groups. One group received Taxotere in combination with cisplatin and fluorouracil and the other group received only cisplatin and fluorouracil. Chemotherapy was administered before radiation treatments. The patients that received the Taxotere experienced a longer survival time and a longer time to disease progression.

Steven Galson, M.D., director of FDA's Center for Drug Evaluation and Research said "Today's approval will provide prescribers with a new treatment option that has been shown to help slow the spread of the disease and prolong patient's survival."